FRLF receives 25 cent short term price target from Ludlow:
Ludlow Research Upgrades Opinion on FRLF Based on New Chairman, and
Hempology Launch
(NEW YORK) – Ludlow Research upgraded its opinion on Freedom Leaf, Inc. (OTCMKTS:
FRLF) based on their pending launch of their Hempology product line, and appointment of Mr.
Pelosi, Jr. as the new Chairman of the Board, with a new ‘speculative’ target of $0.25 per share.